InvestorsObserver

MTNB Matinas Biopharma Hl

$0.19 $0.00 (-1.58%)
15 Minute Delayed Price Enable Real-Time Price
Overall

MTNB Stock Analysis Overview

What this means: InvestorsObserver gives Matinas Biopharma Hl (MTNB) an overall rank of 40, which is below average. Matinas Biopharma Hl is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 40 means that 60% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

MTNB Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

MTNB Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

MTNB Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

MTNB Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

MTNB Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

MTNB Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

MTNB Stock Analysis Overview

What this means: InvestorsObserver gives Matinas Biopharma Hl (MTNB) an overall rank of 40, which is below average. Matinas Biopharma Hl is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 40 means that 60% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full MTNB report

MTNB Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

MTNB Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

MTNB Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

MTNB Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

MTNB Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

MTNB Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Matinas Biopharma Hl (MTNB) Analyst Forecast

MTNB Price, Volume, Earnings, and Dividend Date

  • Last Price $0.19
  • Previous Close $0.19
  • Change $0.00
  • Open $0.20
  • Volume 243,830
  • Avg. Volume (100-day) 1,397,057
  • Market Cap 41,321,738
  • Days Range 0.1824 - 0.195
  • 52-week Range 0.11 - 0.89
  • Dividend Yield
  • Ex. Dividend Date
  • P-E
  • EPS
  • Earnings Date 05/08/24
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta -1.517
  • PEG Ratio

Matinas Biopharma Hl (MTNB) Company Description

Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of product candidates derived from its lipid-crystal nano-particle, or cochleate, delivery technology platform. The firm's pipeline includes MAT2203, MAT2501 and others.

Matinas Biopharma Hl (MTNB) Stock Chart